MD | DC | VA
Our Goal: To become a Top 3 BioHealth Hub by 2023.
Driving Innovation and Entrepreneurship
- World–renowned research institutions and universities
- Influential policymakers and advocacy groups pioneering new health strategies
- World–leading infectious disease research and vaccine development
- Fastest growing region for healthcare companies in the U.S.
- Rated #1 in the nation for science and engineering talent
- Mission control for the National Cancer Moonshot Initiative
Founding Partners
The Company is Hiring Additional Staff to Support its Awards Totaling Over $9 Million ROCKVILLE, Md., Oct. 10, 2019 /PRNewswire/ — Emmes today announced the award of eight new task order contract…
Viela Bio is eligible to receive an upfront licensing fee of $30 million as well as development and commercialization milestones and payments based, in part, on sales revenue GAITHERSBURG, M.D.,…
October 7, 2019 On October 4th, 2019, Intralytix officially opened its brand new 33,000 sq. ft. facility in Columbia, Maryland. The new facility is located in the Columbia Gateway Community…
CAMBRIDGE, Mass. and GAITHERSBURG, Md., Oct. 07, 2019 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and MaxCyte, Inc., the global cell-based therapies and life…
October 04, 2019 Original Press Release GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR)…
October 3, 2019 It has been just 20 months since Viela Bio was founded and today Viela Bio CEO Bing Yao, surrounded by colleagues and family, rang the opening Nasdaq…